Drug Warning Labels: FDA Seeks Feedback Loop
Published Date: 1/27/2026
Notice
Summary
The FDA wants your thoughts on how they collect info about Medication Guides that come with prescription drugs. This affects drug makers and patients who rely on these guides to use medicines safely. You’ve got until March 30, 2026, to share your comments, helping shape how these important guides are handled without adding extra costs or paperwork.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Drugmakers’ Large Time Burden
Holders and sponsors of drug applications will prepare and submit Medication Guides: FDA estimates 70 application holders will each submit one Medication Guide annually and spend about 320 hours each (total ~22,400 hours). FDA also estimates one sponsor will request an exemption annually (4 hours), for a combined total of 71 responses and 22,404 hours annually.
Distributors’ Distribution Workload
FDA estimates 191 distributors will provide Medication Guides to about 9,000 authorized dispensers annually, resulting in 1,719,000 disclosures and an average burden of 1.25 hours per disclosure (total ~2,148,750 hours per year).
Pharmacies’ Time to Give Guides to Patients
FDA estimates 88,736 authorized dispensers (pharmacies/pharmacists) will make about 506,238,880 disclosures annually, spending about 3 minutes (0.05 hours) per disclosure for a total of ~25,311,944 hours per year to provide Medication Guides to patients as required by 21 CFR 208.24(e).
Patients Receive Required Medication Guides
Medication Guides are required to be provided directly to the patient (or the patient's agent) upon dispensing for applicable prescription drugs; FDA says these guides give important information about approved uses, contraindications, adverse reactions, and cautions and are intended to help patients use certain medications most safely and effectively.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-01575 — Determination of Regulatory Review Period for Purposes of Patent Extension; IMAAVY
The FDA has officially set the review period for IMAAVY, a human biological product, which helps the company extend its patent protection. If anyone thinks the dates are wrong, they have until March 30, 2026, to speak up. Also, people can challenge whether the company acted quickly enough during the review by July 27, 2026. This means more time and money could be on the line for the patent holder and competitors.
Next: 2026-01577 — Determination of Regulatory Review Period for Purposes of Patent Extension; BIMZELX
The FDA has officially set the review period for BIMZELX, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to keep exclusive rights, which can impact when generic versions hit the market. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until March 30 or July 27, 2026, to speak up.